NanoViricides, Inc. — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended March 31, 2015, and the nine months ended March 31, 2015—not 2014 Q3 as indicated in the request metadata. Financial statements are unaudited; prior-year comparative figures are identified as restated.
Business context
NanoViricides is a pre-revenue biotechnology company developing antiviral drug candidates. Its programs remain preclinical and are based on technology exclusively licensed from TheraCour Pharma, an entity controlled by a significant stockholder. The company acquired a pilot manufacturing and laboratory facility in Shelton, Connecticut, and reported that commissioning and validation work was ongoing.
Financial performance and position
| Metric | Three months ended March 31, 2015 | Nine months ended March 31, 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $546,464 | $2,274,310 |
| General and administrative expense | $576,173 | $2,352,115 |
| Operating loss | $1,122,637 | $4,626,425 |
| Net income (loss) | $(251,018) | $(1,280,461) |
| Net income (loss) per share, basic | $(0.00) | $(0.02) |
There is no product revenue, so product margins are not applicable. Nine-month cash used in operating activities was $4.96 million; investing activities used $4.56 million, including $5.56 million of property and equipment purchases. Financing provided $6.74 million, principally from warrant exercises. Cash declined $2.78 million to $33.92 million.
At March 31, 2015, current assets were $34.29 million and current liabilities were $523,429. Total liabilities were $13.74 million, including $6.87 million of Series B and C debentures net of discounts and $6.35 million of derivative liabilities. The debentures’ stated principal amounts were $6 million (Series B) and $5 million (Series C). Accumulated deficit was $53.18 million; stockholders’ equity was $31.86 million. Common shares outstanding were 57.15 million.
Changes versus prior comparable periods
- For the nine months, net loss narrowed to $1.28 million from the restated $6.60 million loss in 2014. A major driver was a $6.46 million noncash gain from changes in derivative fair value, versus a $1.59 million gain in the prior-year period; this gain does not represent operating revenue or cash generation.
- Nine-month operating expenses decreased to $4.63 million from $4.87 million. R&D expense fell by $656,126, while G&A expense rose by $408,992.
- For the quarter, the company reported a $251,018 net loss compared with restated net income of $1.32 million in the prior-year quarter, largely reflecting lower derivative fair-value gains.
- Cash decreased from $36.70 million at June 30, 2014. Net property and equipment increased to $10.91 million from $5.50 million, reflecting facility investment.
Outlook, commentary, risks and unusual items
- Management said available cash was sufficient to fund operations through at least March 31, 2017 at the then-current spending rate. It also cautioned that cash may not fully support the business plan and that timelines and cost estimates are uncertain. The company anticipates additional financing may be needed if costs exceed estimates or it accelerates programs.
- Management estimated approximately $12 million of R&D, $4 million of corporate overhead, $2 million of capital costs and $4 million of staffing costs over the next 24 months. It separately estimated about $2 million for FluCide Phase I trials and $5 million for Phase IIa trials if initiated.
- All drug candidates were still in development. FluCide was the most advanced; management described favorable rat safety-study results but said larger-scale production and further toxicology work were needed before an IND filing. The Shelton facility required additional equipment, validation and cGMP process development.
- After quarter-end, the company reported greater than 85% survival in a lethal mouse herpes study, compared with less than 58% for the acyclovir comparator. These are preclinical company-reported findings, not evidence of human efficacy or regulatory approval.
- For Ebola, the filing says initial cell-culture testing indicated that further improvement was needed before advancing the candidates to animal studies. The company was awaiting or pursuing additional testing and potential non-dilutive funding.
- The company restated prior financial statements after identifying omitted derivative liabilities associated with warrant anti-dilution provisions and embedded features in Series C debentures. Management identified a material weakness in controls over review of complex debt and equity transactions and described enhanced senior-management review and use of outside specialists as remediation steps.
- A material related-party transaction was the $4.22 million purchase of the Shelton facility from Inno-Haven, controlled by a significant stockholder. A director and significant stockholder held $9 million in Series B and Series C debentures. The filing reports no pending or threatened legal proceedings known to the company.
Most important facts for investors to verify
- Whether the cash runway remains adequate against actual operating, facility, clinical-trial and scale-up costs, and whether additional financing is required.
- Progress toward cGMP commissioning and validation, IND-enabling studies, and human trials; all programs were preclinical in this filing.
- Assumptions and valuation sensitivity behind the $6.35 million derivative liability and the noncash gains affecting reported earnings.
- Completion and effectiveness of remediation for the material weakness, and whether future filings avoid further restatements.
- Terms, governance review and financial implications of related-party facility and debenture transactions, as well as potential dilution from outstanding warrants, convertible debentures and preferred shares.
- Whether company-reported animal results are independently replicated and translate into regulatory progress; the filing provides no clear evidence of clinical efficacy or product sales.